Department of Medicine I (Clinical Division of Hematology and Hemostaseology)
Position: Doctor-in-training
ORCID: 0009-0002-3806-2250
T +43 1 40400 44170
nikola.vladic@meduniwien.ac.at
Keywords
Antineoplastic Agents; Biomarkers, Pharmacological; Cancer-associated thrombosis ; Cohort Studies; Hemorrhage; Venous Thromboembolism
Research group(s)
- Thrombosis and Haemostasis Research Group
Head: Cihan Ay
Research Area: Our research focuses on thrombosis and haemostasis, with a particular interest in improving the understanding of risk, clinical course and mechanisms of venous thrombosis and bleeding disorders such as haemophilia. The Thrombosis & Haemostasis Research Group is part of the Department of Medicine I, Clinical Division of Haemotology and Haemostaseology, and jointly affiliated with Comprehensive Cancer Center, Cardiovascular Cluster and the Comprehensive Center for Cardiovascular Medicine.
Members:
Research interests
My research focuses on haematology and oncology, with an emphasis on haemostasis and the risks of thrombosis and bleeding in patients with malignancy.
Links:
https://www.researchgate.net/profile/Nikola-Vladic?ev=hdr_xprf
https://orcid.org/my-orcid?orcid=0009-0002-3806-2250
https://pubmed.ncbi.nlm.nih.gov/?term=nikola+vladic&sort=date
Techniques, methods & infrastructure
- Thrombin generation assay
- Plasmin generation assay
- Extracellular tissue factor activity assay
- Soluble P-selectin (sP-selectin) assay
- Citrullinated histone H3–DNA (citH3–DNA)–based quantification of neutrophil extracellular traps (NETs)
Translational research laboratory techniques, including work with biobanked patient plasma samples and ELISA-based measurements.
Assays performed:
Selected publications
- Vladic, N. et al. (2025) ‘Large language models vs thrombosis experts: a comparative study on patient education and clinical decision-making in venous thromboembolism’, Journal of Thrombosis and Haemostasis [Preprint]. Available at: https://doi.org/10.1016/j.jtha.2025.09.004.
- Vladić, N. et al. (2025) ‘Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies’, Blood Advances, 9(13), pp. 3340–3349. Available at: https://doi.org/10.1182/bloodadvances.2025016044.
- Vladic, N. et al. (2025) ‘Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED study’, Research and Practice in Thrombosis and Haemostasis, 9(4), p. 102933. Available at: https://doi.org/10.1016/j.rpth.2025.102933.
- Vladic, N. et al. (2025) ‘Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies’, Research and Practice in Thrombosis and Haemostasis, 9(1), p. 102664. Available at: https://doi.org/10.1016/j.rpth.2024.102664.